Tomohiko Akahoshi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tomohiko Akahoshi has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Morimasa Tomikawa
Center of Integration of Advanced Medicine, Life Science and Innovative Technology; Kyushu University; Fukuoka Japan
6 shared publicationsYoshihiko Maehara
Department of Surgery and Science; Graduate School of Medical Sciences; Kyushu University; Fukuoka Japan
5 shared publicationsMakoto Hashizume
Center of Integration of Advanced Medicine, Life Science and Innovative Technology; Kyushu University; Fukuoka Japan
4 shared publicationsHirofumi Kawanaka
Department of Surgery and Science; Graduate School of Medical Sciences; Kyushu University; Fukuoka Japan
3 shared publicationsNao Kinjo
Department of Surgery and Science, Kyushu University, Fukuoka, Japan
3 shared publicationsYoshihiro Nagao
Department of Surgery and Science, Kyushu University, Fukuoka, Japan
3 shared publications
Latest Publications
- 20 November 2014
- Published by Springer Nature in European Journal of Trauma and Emergency Surgery
- Vol. 41 (5) , 531-538
Comparison of recombinant human thrombomodulin and gabexate mesylate for treatment of disseminated intravascular coagulation (DIC) with sepsis following emergent gastrointestinal surgery: a retrospective study
- 20 November 2014
- Published by Springer Nature in European Journal of Trauma and Emergency Surgery
- Vol. 41 (5) , 531-538
Comparison of recombinant human thrombomodulin and gabexate mesylate for treatment of disseminated intravascular coagulation (DIC) with sepsis following emergent gastrointestinal surgery: a retrospective study
- 20 January 2012
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 27 (2) , 286-290
Laparoscopic splenectomy with interferon therapy in 100 hepatitis-C-virus-cirrhotic patients with hypersplenism and thrombocytopenia
We intended to determine whether laparoscopic splenectomy (Lap-Sp) contributes to treatment with interferon therapy in hepatitis C virus (HCV)-cirrhotic patients with thrombocytopenia caused by hypersplenism. From December 2004 to August 2008, 100 cirrhotic patients (54 men and 46 women) underwent Lap-Sp for a clinical application of interferon therapy. All the patients were Child-Pugh class A or B with thrombocytopenia (average platelet count, 56 × 10(3) /mm(3)). The HCV genotype was type 1 in 80 patients and type 2 in 20 patients. Pure laparoscopic or hand-assisted laparoscopy was performed in 78 and 22 patients, respectively, without mortality. Conversion to open surgery was not required in any of the patients. The platelet counts improved (mean platelet count 172 × 10(3) /mm(3) 1 month after surgery) and interferon (IFN) therapy was started in 97 patients. In this study period, 36 patients obtained a sustained virologic response. Eight patients discontinued IFN therapy because of depression, neutropenia or other reasons. Lap-Sp permits most patients with HCV cirrhosis and hypersplenism to receive sufficient IFN therapy. Therefore, Lap-Sp can become a strong supportive surgery for cirrhotic patients who require antiviral therapy.
- 20 January 2012
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 27 (2) , 286-290
Laparoscopic splenectomy with interferon therapy in 100 hepatitis-C-virus-cirrhotic patients with hypersplenism and thrombocytopenia
We intended to determine whether laparoscopic splenectomy (Lap-Sp) contributes to treatment with interferon therapy in hepatitis C virus (HCV)-cirrhotic patients with thrombocytopenia caused by hypersplenism. From December 2004 to August 2008, 100 cirrhotic patients (54 men and 46 women) underwent Lap-Sp for a clinical application of interferon therapy. All the patients were Child-Pugh class A or B with thrombocytopenia (average platelet count, 56 × 10(3) /mm(3)). The HCV genotype was type 1 in 80 patients and type 2 in 20 patients. Pure laparoscopic or hand-assisted laparoscopy was performed in 78 and 22 patients, respectively, without mortality. Conversion to open surgery was not required in any of the patients. The platelet counts improved (mean platelet count 172 × 10(3) /mm(3) 1 month after surgery) and interferon (IFN) therapy was started in 97 patients. In this study period, 36 patients obtained a sustained virologic response. Eight patients discontinued IFN therapy because of depression, neutropenia or other reasons. Lap-Sp permits most patients with HCV cirrhosis and hypersplenism to receive sufficient IFN therapy. Therefore, Lap-Sp can become a strong supportive surgery for cirrhotic patients who require antiviral therapy.
- 19 December 2011
- Published by Wiley in Hepatology Research
- Vol. 42 (4) , 385-393
Impact of balloon‐occluded retrograde transvenous obliteration on management of isolated fundal gastric variceal bleeding
Aim: Although endoscopic injection of cyanoacrylate (CA) is the only effective method for treating isolated fundal gastric variceal bleeding, the rebleeding rate is relatively high. This study investigated the efficacy of balloon‐occluded retrograde transvenous obliteration (B‐RTO) for management of isolated fundal gastric variceal bleeding.Methods: Patients (n = 110) with acute or recent bleeding from isolated fundal gastric varices (GV) were retrospectively studied. Acute bleeding was treated by CA injection or balloon tamponade. 44 patients underwent additional endoscopic injection of CA and ethanolamine oleate (EO) weekly until obturation of GVx from 1994 to 2002 (group A). 42 patients from 2003 to 2010 underwent B‐RTO after initial hemostasis (group B). Both groups were assessed for the number of sessions required to achieve GV obturation, hospital stay, recurrent bleeding rate, morbidity and mortality.Results: Acute gastric variceal bleeding was successfully treated in all patients by CA injection or balloon tamponade. B‐RTO was successfully performed except in two patients in group B. The average number of sessions required for obturation was 3.8 for groups A and 2.2 for B (P < 0.05). Recurrent bleeding was observed in 16 and two patients in groups A and B, respectively. The cumulative non‐rebleeding rate at 5 years was 58.3% and 98.1% in groups A and B, respectively. The cumulative survival rate at 5 years was 53.8% and 87.6% in groups A and B, respectively.Conclusion: Balloon‐occluded retrograde transvenous obliteration may be superior to endoscopic injection with CA and EO for prevention of rebleeding in patients with isolated fundal GVs with a major shunt.
- 19 December 2011
- Published by Wiley in Hepatology Research
- Vol. 42 (4) , 385-393
Impact of balloon‐occluded retrograde transvenous obliteration on management of isolated fundal gastric variceal bleeding
Aim: Although endoscopic injection of cyanoacrylate (CA) is the only effective method for treating isolated fundal gastric variceal bleeding, the rebleeding rate is relatively high. This study investigated the efficacy of balloon‐occluded retrograde transvenous obliteration (B‐RTO) for management of isolated fundal gastric variceal bleeding.Methods: Patients (n = 110) with acute or recent bleeding from isolated fundal gastric varices (GV) were retrospectively studied. Acute bleeding was treated by CA injection or balloon tamponade. 44 patients underwent additional endoscopic injection of CA and ethanolamine oleate (EO) weekly until obturation of GVx from 1994 to 2002 (group A). 42 patients from 2003 to 2010 underwent B‐RTO after initial hemostasis (group B). Both groups were assessed for the number of sessions required to achieve GV obturation, hospital stay, recurrent bleeding rate, morbidity and mortality.Results: Acute gastric variceal bleeding was successfully treated in all patients by CA injection or balloon tamponade. B‐RTO was successfully performed except in two patients in group B. The average number of sessions required for obturation was 3.8 for groups A and 2.2 for B (P < 0.05). Recurrent bleeding was observed in 16 and two patients in groups A and B, respectively. The cumulative non‐rebleeding rate at 5 years was 58.3% and 98.1% in groups A and B, respectively. The cumulative survival rate at 5 years was 53.8% and 87.6% in groups A and B, respectively.Conclusion: Balloon‐occluded retrograde transvenous obliteration may be superior to endoscopic injection with CA and EO for prevention of rebleeding in patients with isolated fundal GVs with a major shunt.
- 1 July 2011
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 27 (1) , 137-141
Prediction of improved liver function after balloon‐occluded retrograde transvenous obliteration: Relation to hepatic vein pressure gradient
Background and Aims: Balloon‐occluded retrograde transvenous obliteration (B‐RTO) is an effective treatment for gastric varices (GVx), as well as hepatic encephalopathy. The aim of this study was to examine the changes of the hepatic vein pressure gradient (HVPG) after B‐RTO and determine the relation between the changes of HVPG and liver function.Patients and Methods: B‐RTO was performed in 30 patients with GVx and hepatic encephalopathy. HVPG was measured in 19 of 30 patients both before and after B‐RTO.Results: The B‐RTO was successful in all patients. The GVx and hepatic encephalopathy were improved, and no recurrence or bleeding was observed within the follow‐ up period. The serum albumin and prothrombin activity were significantly improved 6 months after B‐RTO in all patients. HVPG was elevated 44% above the baseline after B‐RTO. Liver function significantly improved 6 months after B‐RTO in patients whose HVPG increased ≥ 20% from baseline.Conclusion: An elevated HVPG after B‐RTO is one aspect of the effect of liver function, and an HVPG increase of ≥ 20% from baseline is a predictive factor for obtaining an improvement of liver function.
- 1 July 2011
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 27 (1) , 137-141
Prediction of improved liver function after balloon‐occluded retrograde transvenous obliteration: Relation to hepatic vein pressure gradient
Background and Aims: Balloon‐occluded retrograde transvenous obliteration (B‐RTO) is an effective treatment for gastric varices (GVx), as well as hepatic encephalopathy. The aim of this study was to examine the changes of the hepatic vein pressure gradient (HVPG) after B‐RTO and determine the relation between the changes of HVPG and liver function.Patients and Methods: B‐RTO was performed in 30 patients with GVx and hepatic encephalopathy. HVPG was measured in 19 of 30 patients both before and after B‐RTO.Results: The B‐RTO was successful in all patients. The GVx and hepatic encephalopathy were improved, and no recurrence or bleeding was observed within the follow‐ up period. The serum albumin and prothrombin activity were significantly improved 6 months after B‐RTO in all patients. HVPG was elevated 44% above the baseline after B‐RTO. Liver function significantly improved 6 months after B‐RTO in patients whose HVPG increased ≥ 20% from baseline.Conclusion: An elevated HVPG after B‐RTO is one aspect of the effect of liver function, and an HVPG increase of ≥ 20% from baseline is a predictive factor for obtaining an improvement of liver function.
- 19 August 2009
- Published by Springer Nature in Surgical Endoscopy
- Vol. 24 (3) , 680-685
Laparoscopic splenectomy with peginterferon and ribavirin therapy for patients with hepatitis C virus cirrhosis and hypersplenism
- 19 August 2009
- Published by Springer Nature in Surgical Endoscopy
- Vol. 24 (3) , 680-685
Laparoscopic splenectomy with peginterferon and ribavirin therapy for patients with hepatitis C virus cirrhosis and hypersplenism
- 19 November 2008
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 23 (11) , 1702-1709
Long‐term results of balloon‐occluded retrograde transvenous obliteration for gastric variceal bleeding and risky gastric varices: A 10‐year experience
Background and Aim: Balloon‐occluded retrograde transvenous obliteration (B‐RTO) is a new alternative treatment for gastric varices (GVx), but the long‐term efficacy is not known. We investigated the long‐term effects of B‐RTO on rebleeding, prevention of first bleeding, mortality and occurrence of risky esophageal varices (EVx).Methods: B‐RTO was performed in 68 cirrhotic patients with GVx. Twenty patients had recent bleeding, transiently treated by endoscopic Histoacryl injection or balloon tamponade. Forty‐eight patients had varices likely to bleed, but no bleeding. After B‐RTO, the recurrent bleeding, occurrence of EVx and mortality over the long‐term were evaluated.Results: B‐RTO was successfully performed in 63 of 68 patients (92.6%). Varices eradication was confirmed by endoscopy in 61 of 63 patients (96.6%). During follow up, GVx bleeding occurred in two patients (3.2%). The 8‐year cumulative rebleeding rates of patients with bleeding and risky GVx were 14% and 0%, respectively. Risky EVx occurred in 10 patients (17%) and the cumulative occurrence rate was 22% in 8 years. The cumulative occurrence rate of risky EVx was higher in GVx with EVx (GOV2‐GVx) compared to GVx without EVx (IGV1, P < 0.05). No ectopic variceal bleeding occurred. No patients died from variceal bleeding. Hepatocellular carcinoma was the only significant prognostic factor (P < 0.05).Conclusion: B‐RTO is beneficial over the long‐term, despite worsening EVx in some patients, because of excellent treatment efficacy and improved mortality. We believe that B‐RTO can become a first‐choice radical treatment following hemostasis for gastric variceal bleeding and prophylactic treatment for risky GVx.
- 19 November 2008
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 23 (11) , 1702-1709
Long‐term results of balloon‐occluded retrograde transvenous obliteration for gastric variceal bleeding and risky gastric varices: A 10‐year experience
Background and Aim: Balloon‐occluded retrograde transvenous obliteration (B‐RTO) is a new alternative treatment for gastric varices (GVx), but the long‐term efficacy is not known. We investigated the long‐term effects of B‐RTO on rebleeding, prevention of first bleeding, mortality and occurrence of risky esophageal varices (EVx).Methods: B‐RTO was performed in 68 cirrhotic patients with GVx. Twenty patients had recent bleeding, transiently treated by endoscopic Histoacryl injection or balloon tamponade. Forty‐eight patients had varices likely to bleed, but no bleeding. After B‐RTO, the recurrent bleeding, occurrence of EVx and mortality over the long‐term were evaluated.Results: B‐RTO was successfully performed in 63 of 68 patients (92.6%). Varices eradication was confirmed by endoscopy in 61 of 63 patients (96.6%). During follow up, GVx bleeding occurred in two patients (3.2%). The 8‐year cumulative rebleeding rates of patients with bleeding and risky GVx were 14% and 0%, respectively. Risky EVx occurred in 10 patients (17%) and the cumulative occurrence rate was 22% in 8 years. The cumulative occurrence rate of risky EVx was higher in GVx with EVx (GOV2‐GVx) compared to GVx without EVx (IGV1, P < 0.05). No ectopic variceal bleeding occurred. No patients died from variceal bleeding. Hepatocellular carcinoma was the only significant prognostic factor (P < 0.05).Conclusion: B‐RTO is beneficial over the long‐term, despite worsening EVx in some patients, because of excellent treatment efficacy and improved mortality. We believe that B‐RTO can become a first‐choice radical treatment following hemostasis for gastric variceal bleeding and prophylactic treatment for risky GVx.